John Fesko, President and Chief Business Officer at Natera, shared a post on LinkedIn:
“15 years ago, seeing someone I love decline chemo for muscle-invasive bladder cancer sparked my interest in circulating tumor DNA. Today, Genentech’s Phase 3 Atezolizumab results, as Professor Thomas Powles notes, open the door to ‘a new treatment paradigm’ for patients who are ‘positive for recurrence on a molecular level but have no evidence of disease on imaging.'”
Read More about IMvigor011 Trial on OncoDaily.
